INDICATIONS

REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

REBLOZYL limits transfusions1

Learn more about how REBLOZYL can help patients with anemia due to MDS-RS or beta-thalassemia

In the MEDALIST study, the primary endpoint was RBC transfusion independence ≥8 weeks during Weeks 1-24.

In the BELIEVE study, the primary endpoint was ≥33% reduction in RBC transfusion burden of at least 2 units from Weeks 13-24.

MDS-RS=myelodysplastic syndromes with ring sideroblasts; RBC=red blood cell.

REBLOZYL limits transfusions1

Learn more about how REBLOZYL can help patients with anemia due to MDS-RS or beta-thalassemia

In the MEDALIST study, the primary endpoint was RBC transfusion independence ≥8 weeks during Weeks 1-24.

In the BELIEVE study, the primary endpoint was ≥33% reduction in RBC transfusion burden of at least 2 units from Weeks 13-24.

MDS-RS=myelodysplastic syndromes with ring sideroblasts; RBC=red blood cell.